Catalent (NYSE:CTLT) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

A number of other equities analysts have also issued reports on the stock. BidaskClub lowered shares of Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. Piper Jaffray Companies raised their target price on shares of Catalent from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 7th. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 target price on the stock in a research report on Monday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Catalent in a research report on Monday, October 23rd. Finally, Morgan Stanley upgraded shares of Catalent from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $29.00 to $48.00 in a research report on Thursday, September 21st. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $44.25.

Shares of Catalent (CTLT) traded down $0.99 during trading on Friday, reaching $38.80. 612,803 shares of the company’s stock traded hands, compared to its average volume of 894,161. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49. The stock has a market capitalization of $5,154.93, a price-to-earnings ratio of 27.13, a P/E/G ratio of 2.49 and a beta of 1.42. Catalent has a one year low of $23.03 and a one year high of $43.39.

Catalent (NYSE:CTLT) last announced its earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.01. The business had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period last year, the firm posted $0.16 earnings per share. sell-side analysts predict that Catalent will post 1.46 earnings per share for the current year.

In related news, Director Uwe Roehrhoff purchased 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The stock was purchased at an average cost of $39.22 per share, with a total value of $294,150.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.70% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Advisor Group Inc. lifted its holdings in shares of Catalent by 1.3% during the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after purchasing an additional 65 shares during the period. Stifel Financial Corp lifted its holdings in shares of Catalent by 0.9% during the second quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after purchasing an additional 96 shares during the period. Aperio Group LLC lifted its holdings in shares of Catalent by 0.8% during the second quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock worth $810,000 after purchasing an additional 190 shares during the period. Capstone Asset Management Co. lifted its holdings in shares of Catalent by 2.3% during the second quarter. Capstone Asset Management Co. now owns 10,130 shares of the company’s stock worth $356,000 after purchasing an additional 230 shares during the period. Finally, People s United Financial Inc. lifted its holdings in shares of Catalent by 1.9% during the second quarter. People s United Financial Inc. now owns 18,952 shares of the company’s stock worth $665,000 after purchasing an additional 356 shares during the period. 99.44% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/valuengine-downgrades-catalent-ctlt-to-hold/1741688.html.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.